Oncology-based In-Vivo CRO Global Market Report 2024

The oncology based in-vivo cro market has grown strongly in recent years. It will grow from $1.27 billion in 2023 to $1.38 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth observed in the historical period can be attributed to several factors, including a heightened focus on oncology therapeutics, the rising incidence of cancer cases, a notable shift towards personalized medicine within the healthcare landscape, the overall growth of the pharmaceutical industry, and an increased demand for therapies targeting specific molecular or cellular markers associated with cancer.

The oncology based in-vivo cro market is expected to see strong growth in the next few years. It will grow to $2 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. Anticipated growth in the forecasted period is expected to arise from emerging market prospects, a shift towards immuno-oncology therapies, an increase in the number of oncology clinical trials, the continued development of precision medicine and targeted therapies. Major trends projected for this period encompass advancements in regenerative medicine and cell therapies, a heightened demand for accelerated drug development processes, the integration of digitalization and data analytics in oncology research, a concentrated focus on understanding the tumor microenvironment, and an upsurge in the development and application of biologics and immunotherapies.

The anticipated surge in cancer cases is set to propel the expansion of the oncology-based in-vivo CRO market. Cancer, characterized by uncontrolled cell division and spread, necessitates innovative drugs and devices, prompting various preclinical and clinical trials for effective treatments. Oncology in-vivo CROs aid in these critical stages, conducting preclinical in-vivo studies to assess drugs or devices before human trials. The escalating cancer prevalence drives the demand for advanced treatments, consequently boosting the oncology-based in-vivo CRO market. As per the American Chemical Society, a 47% rise to 28.4 million cancer cases is forecasted by 2040 from 2020, reflecting the market's growth propelled by increasing cancer prevalence.

The upsurge in healthcare spending is expected to drive the expansion of the oncology-based in-vitro CRO market. Healthcare expenditure, encompassing costs related to healthcare services, significantly influences the development and accessibility of in-vitro CRO services within the oncology sector. Notably, the Canadian Institute for Health Information reported a rise in healthcare expenditure to $331 billion in 2022, indicating an 0.8% increase from the previous year. This surge in spending accentuates the market's growth within the oncology-based in-vitro CRO domain.

Major companies within the oncology-based in-vivo CRO market are keen on innovating to maintain their market positions. Crown Bioscience's launch of the 3D Ex Vivo Patient Tissue Platform in October 2021 exemplifies this trend. This platform, utilizing phenotypic 3D models of fresh patient tumors and high-content imaging analysis, enhances predictability for immuno-oncology drug candidates. It allows for relevant drug response analysis, aiding candidate selection and clinical program design.

Companies within this market segment are focusing on novel solutions such as CAR T-cell therapies to gain a competitive edge. For instance, Seattle Children's Hospital and Research Institute launched BrainChild Bio in May 2023, targeting CAR T-cell therapies for pediatric brain tumors such as diffuse intrinsic pontine gliomas (DIPG). This platform incorporates synthetic technologies to enhance CAR T-cell therapy for CNS malignancies, aiming to expand its applications to other challenging brain tumors such as glioblastoma and brain metastases. The pursuit of these innovative therapies signifies a strategic move to advance treatment options within the oncology-based in-vivo CRO market.

In March 2023, ClinChoice Medical Development, a US-based contract research organization (CRO) that provides research services to accelerate drug and device approvals, acquired Cromsource S.r.l. for an undisclosed amount. Through this acquisition, ClinChoice Medical Development expands its operational capabilities with additional delivery hubs to complement its existing network in Europe and the US. Data science technology offerings in several areas, including risk-based monitoring and decentralized clinical trials, are expanded through acquisition. Cromsource S.r.l. is an Italy-based contract research organization that provides full-research services to the pharmaceutical, biotechnology, and medical device industries.

Major companies operating in the oncology based in-vivo cro market report are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

North America was the largest region in the oncology based in-vivo CRO market in 2023. North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncology based in-vivo cro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary areas of focus for oncology-based in-vivo CROs encompass blood cancer, solid tumors, and other related indications. Blood cancers originate from tissues responsible for blood formation, such as immune cells and bone marrow, including leukemia, lymphoma, and multiple myeloma. These CROs provide in-vivo testing services utilizing models such as blood cancer-based xenografts and others to expedite drug development research, aiding sponsors of drugs and devices in gaining market approval. Various models, including syngeneic, xenograft, patient-derived xenograft (PDX), and others, are employed by oncology-based in-vivo CROs and applied within hospital and rehabilitation settings.

The oncology based in-vivo CRO software market research report provides oncology based in-vivo CRO software market statistics, including oncology based in-vivo CRO software industry global market size, regional shares, competitors with a oncology based in-vivo CRO software market share, detailed oncology based in-vivo CRO software market segments, market trends and opportunities, and any further data you may need to thrive in the oncology based in-vivo CRO software industry. This oncology based in-vivo CRO software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology-based in-vivo CRO market includes revenues earned by entities by providing preclinical research services such as in-vivo testing via models such as Orthotopic tumor models, tumor passaging, tissue culture models, and others for oncology drugs and devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.